Reviva Pharmaceuticals Holdings, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $5.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-12
- Reviva Pharmaceuticals Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $7.75M.
- Reviva Pharmaceuticals Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$8.19M.
- Reviva Pharmaceuticals Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$11.39M.
- Reviva Pharmaceuticals Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$7.26M.
- Reviva Pharmaceuticals Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $962.46K.
- Reviva Pharmaceuticals Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$9.89M, a 304.04% decline from fiscal 2023.
- Reviva Pharmaceuticals Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $4.85M.
- Reviva Pharmaceuticals Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$11.17M, a 153.37% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.45M 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $7.75M 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $962.46K 10-K · filed 2026-03-30 | |||
| 2025-09-30 | -$293.07K 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | -$3.11M 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | -$8.19M 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | -$9.89M 10-K · filed 2026-03-30 | |||
| 2024-09-30 | -$17.81M 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | -$17.19M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$11.39M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $4.85M 10-K · filed 2025-04-03 | |||
| 2023-09-30 | -$13.55M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$7.37M 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | -$7.26M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | -$11.17M 10-K · filed 2024-04-15 | |||
| 2022-09-30 | -$6.50M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$10.27M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$6.27M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $20.93M 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $24.73M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $27.04M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | -$3.12M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $8.76M 10-K · filed 2022-03-15 | |||
| 2020-09-30 | $353.06K 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $194.60K 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | $169.34K 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | -$118.44K 10-K/A · filed 2021-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |